Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OGD203
- Development stage
- Preclinical
- Lead developer
- OGD2 Pharma
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
OGD203 is a preclinical-stage chimeric antigen receptor (CAR) cell therapy being developed by OGD2 Pharma. It is designed to target O-acetylated-GD2 (OAcGD2), a tumor-associated ganglioside that is highly expressed on various neuroectoderm-derived tumors, such as neuroblastoma, melanoma, and certain sarcomas, while having limited expression in normal tissues. By engineering T-cells or NK-cells to express a CAR specific for OAcGD2, OGD203 aims to directly recognize and eliminate tumor cells. This approach potentially offers a safety advantage over targeting GD2, as OAcGD2 is not expressed on peripheral nerves, potentially avoiding the severe neuropathic pain associated with anti-GD2 monoclonal antibodies.
- Other names
- CAR-NK targeting O-acetylated-GD2OAcGD2 CAR-NKOAcGD-2 CAR-NKOAcGD 2 CAR-NK
02
Targets
OAcGD2 (O-acetyl-GD2)
Beyond the preview
Go deeper on OGD203.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OGD203.